1. Sweden Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Paxman AB

Paxman AB

SSTO:PAX
64.90
SEK
-1.60
(-2.41%)
-0.22EPS
1.15BMarket Cap
Nov 20Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.64
3.62
5.33
4.87
5.51
7.67
11.05
13.31
13.46
15.91
Basic EPS, GAAP
-0.57
-0.44
0.17
-1.2
-0.73
-0.54
0.44
2.11
-0.72
-0.22
Free Cash Flow per Basic Share
-1.65
-1.14
-1.09
-0.92
-1.6
-1.74
-0.51
0.81
-0.69
-1.17
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
2.05
1.59
1.77
0.68
6.61
6.01
6.45
8.63
17.41
17.91
Tangible Book Value per Share
1.45
0.97
1
-0.1
5.75
4.81
4.65
6.58
9.01
9.93
Basic Weighted Avg Shares
12
16
16
16
17
19
19
19
23
23
Sales/Revenue/Turnover
31
58
85
78
96
146
210
253
313
366
Operating Margin (%)
-21.69
-8.24
-6.99
-14.98
-11
-0.85
6.01
13.24
1.36
0.53
Depreciation Expense
2
5
8
11
13
17
19
16
24
36
Net Income, GAAP
-7
-7
3
-19
-13
-10
8
40
-17
-5
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
3.14
- -
374.82
Profit Margin (%)
-21.46
-12.24
3.23
-24.58
-13.28
-7.08
3.96
15.89
-5.33
-1.38
Working Capital
13
-8
-10
-20
74
42
44
75
167
188
LT Debt
- -
- -
14
16
6
4
3
1
3
3
Total Equity
33
25
28
11
126
114
123
164
405
417
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
20.56
- -
-1.22
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
26.27
- -
-1.16
Return on Common Equity (%)
- -
-24.42
10.25
-97.76
-18.7
-8.61
7.04
28.05
-5.87
-1.2

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
10
1
10
LT Borrowings
3
4
3
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
23
23
23
Market Capitalization
1,308
1,117
1,147

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
223
226
243
Cash, Cash Equivalents & STI
121
106
106
Accounts Receivable, Net
46
81
96
Inventories
33
37
38
Total Current Liabilities
56
50
55
Payables & Accruals
- -
- -
- -
ST Debt
10
1
10
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
246.77%
147.06%
Free Cash Flow
- -
-85.4%
-204.46%
Net Income, GAAP
- -
1.54%
-141.58%
Sales/Revenue/Turnover
- -
32.64%
23.85%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
59
63
65
66
253
2025
67
75
87
84
313
2026
90
105
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.69
0.52
0.26
0.64
2.11
2025
-0.29
-0.14
0.06
-0.38
-0.72
2026
-0.01
0.11
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Richard Jeremy Paxman
Full Time Employees
144
Sector
Health technology
Industry
Medical specialties
Address
Pirgatan 13 Karlshamn BL Sweden 374 35
IPO Date
Jun 12, 2017
Website
paxman.se
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Paxman AB (publ) develops and sells scalp cooling systems to minimize hair loss during chemotherapy treatment; its core product, the Paxman Scalp Cooler, is a mobile electric cooling unit with silicone hats for one or two patients, featuring a touch-screen interface for monitoring; the company also offers single-patient-use cooling caps, insurance-based billing models, and patient assistance programs, with development underway for a device to prevent chemotherapy-induced peripheral neuropathy (CIPN) and collaborations including wearable cooling devices with the University of Huddersfield and University of Leeds, and cooling-compression systems with the National University Hospital of Singapore. Paxman AB (publ) operates worldwide, serving cancer centers and hospitals in primary markets such as Great Britain, Scandinavia, the Netherlands, Belgium, Australia, the United States, and Canada; it targets oncology patients through recurring treatment revenue models, equipment sales, rentals, and regional technician services. Founded in 1996 and headquartered in Karlshamn, Sweden, the company listed on Nasdaq Stockholm under ticker PAX.ST employs approximately 140 people and following its May 2025 acquisition of competitor Dignitana AB (publ) via a public offer valued at SEK 153 million, now integrates the DigniCap system into its portfolio, enhancing US market presence; in March 2025, it raised SEK 123.5 million through a directed share issue to institutional investors including Eiffel Investment Group and Unionen, funding growth including CIPN commercialization, R&D, and a new Huddersfield, UK manufacturing facility by end-2026; recent developments include new Category I CPT codes effective January 2026 for US reimbursement, CMS proposed rates for 2026, and presentation of CIPN trial data at ESMO 2025.